What is Galafold (migalastat) and what is it used for?
Galafold is the brand name for migalastat, an oral medicine used to treat adults with Fabry disease who have certain “amenable” mutations in the GLA gene [1]. Fabry disease is a genetic lysosomal storage disorder where faulty alpha-galactosidase A enzyme function leads to harmful buildup in the body. Migalastat is designed to help stabilize specific mutant forms of alpha-galactosidase A so the enzyme can work more effectively [1].
How does Galafold work (and who qualifies for “amenable” mutations)?
Galafold works by binding selectively to certain mutant alpha-galactosidase A enzymes. For mutations classified as amenable, this binding can improve enzyme trafficking and activity in lysosomes, reducing substrate accumulation [1]. Because not all Fabry-causing mutations respond, patients need genetic testing and must meet the criteria for amenable variants to use Galafold [1].
How is Galafold taken?
Galafold is taken by mouth on a fixed dosing schedule (once every other day) [1]. Exact dosing and timing instructions should come from the prescribing clinician, based on the patient’s overall regimen and medical history [1].
What side effects do people report with Galafold?
Commonly reported side effects for Galafold include headache, nausea, and dizziness [1]. Patients should discuss their specific risk factors and report any concerning symptoms to their care team [1].
How does Galafold compare with enzyme replacement therapy for Fabry disease?
For Fabry disease, there are two broad treatment approaches: enzyme replacement therapy (ERT) and pharmacologic chaperone therapy with migalastat (Galafold). Galafold is only for patients with amenable mutations, while ERT can be used regardless of genotype for many patients [1]. The best choice depends on mutation status, treatment goals, convenience, tolerability, and clinician assessment [1].
What should patients ask their doctor before starting Galafold?
Patients typically need to confirm whether their specific GLA mutation is amenable and understand how treatment response will be monitored [1]. They may also want to review potential drug interactions, dosing consistency, and what clinical and lab markers the clinician will follow over time [1].
Sources
- Galafold (migalastat) prescribing information and product monograph - FDA/official label references via Drugs.com